Premium
p21/waf1/cip1 and mdm‐2 expression in breast carcinoma patients as related to prognosis
Author(s) -
Jiang Ming,
Shao ZhiMing,
Wu Jun,
Lu JingSong,
Yu LiMing,
Yuan JianDa,
Han QiXia,
Shen ZhenZhou,
Fontana Joseph A.
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19971021)74:5<529::aid-ijc9>3.0.co;2-5
Subject(s) - carcinogenesis , cancer research , breast cancer , breast carcinoma , lymph node , carcinoma , biology , tumor progression , oncology , immunohistochemistry , cancer , medicine
p21/waf1/cip1 and mdm‐2 are downstream effectors of p53. p21 plays a major role in negatively regulating cell‐cycle progression, while mdm‐2 inhibits p53 effects, and its role has been implicated in oncogenesis. In this study, we investigated the expression profiles of p21, mdm‐2 and p53 in human breast‐carcinoma tissues. The aim was to determine whether a correlation exists between the expression profiles of these markers and tumor differentiation, ER status and prognosis. We studied tumor specimens obtained from 106 patients and found a highly significant association among low histology grade, p53 over‐expression, high mdm‐2 expression and lack of p21 expression. Our studies also demonstrate that, in human breast cancer, low levels of p21 and higher mdm‐2 levels directly correlate with the onset of lymph‐node metastases and shortened patient survival. Furthermore, the expression profiles of p21, mdm‐2 and p53 were independently correlated with patient survival. Int. J. Cancer 74:529–534, 1997. © 1997 Wiley‐Liss, Inc.